Several bsAbs (AMG330, AMV564, and AMG673) targeting CD33+ AML are being evaluated in preclinical and early clinical trials (NCT02520427, NCT03144245, NCT03224819) to determine their efficacy as immunotherapeutic agents. This evidence concerns the gene CD33 and acute myeloid leukemia.